Phase II Study of Alisertib as a Single Agent in Recurrent and Refractory Central Nervous System Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

Trial Profile

Phase II Study of Alisertib as a Single Agent in Recurrent and Refractory Central Nervous System Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Alisertib (Primary) ; Carboplatin; Cisplatin; Cyclophosphamide; Etoposide; Methotrexate; Topotecan; Vincristine
  • Indications Rhabdoid tumour; Teratoma
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Acronyms SJATRT
  • Most Recent Events

    • 07 Mar 2018 Planned End Date changed from 31 May 2027 to 1 May 2027.
    • 07 Mar 2018 Planned primary completion date changed from 31 May 2023 to 1 May 2023.
    • 23 Feb 2015 Planned number of patients changed from 160 to 180 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top